ClinicalTrials.gg
RecruitingNCT06578104Updated Nov 12, 2026

PULSED AF Post-Approval Study

An observational study in Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions. Recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 12, 2026Site recruiting status changed6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
580
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Atrial Fibrillation by Medtronic — 8 open to participants now, 12 under way, none of them phase 3. Atrial Fibrillation · Medtronic.

Planned enrollment
10th of 18
580 · median 777
Started
2024
with 1 other
Observational
18 of 84
2 open now
Primary completion
2027-04
later than 3 of 11 live
Registered
78th of 84
by date

Among the 84 studies in Atrial Fibrillation by Medtronic, this one is the 10th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2024, is one of 18 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 78th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 84 studies in Atrial Fibrillation by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Atrial Fibrillation by Medtronic, or all of them as a file.
02

Study summary

PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.

Read the detailed description

PulseSelect is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months. Study visits will occur at 3, 6, 12, 24, and 36 months post-ablation, including required 24-hour Holter monitoring at 6, 12, 24, and 36 month visits. The PulseSelect™ PFA System used in this study is market approved and the ablation procedure will be performed according to hospital standard of care.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects 18 years or older with a planned procedure using commercially available PulseSelect™ PFA System

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of recurrent symptomatic paroxysmal AF or persistent AF
  • to at least one Class I or III antiarrhythmic drug (i.e., not effective, not tolerated, or not desired)
  • Patient is ≥ 18 years of age
  • Planned pulmonary vein isolation procedure with the commercially available PulseSelect™ PFA System
  • Willing and able to comply with study requirements and give (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements

Exclusion criteria

Exclusion Criteria

  • Long-standing persistent AF (continuous AF sustained >12 months)
  • Prior left atrial catheter or surgical ablation
  • Patient with \< 36 months
  • Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)
  • Current or anticipated participation in any other clinical trial of a drug, device, or biologic not approved by the global study manager
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
580 participants (estimated)
Patient registry
No

Groups and cohorts

  • Paroxysmal

    Ablation using the PulseSelect™ PFA system

    Device: PulseSelect™ PFA system

  • Persistent

    Ablation using the PulseSelect™ PFA system

    Device: PulseSelect™ PFA system

Interventions

  • DevicePulseSelect™ PFA system

    Ablation using the PulseSelect™ PFA system

06

What researchers measure

Primary outcomes

  1. Efficacy-Freedom from Atrial Fibrillation

    Estimate the 36-month freedom from AF/AFL/AT recurrence following ablation using the PulseSelect™ PFA system.

    Time frame: 36-months after the index ablation procedure

  2. Safety- Freedom from Device/Procedure Related Adverse Events

    Estimate the rate of major procedural complications for catheter ablation using PulseSelect™ PFA system.

    Time frame: 6 months post-ablation]

07

Study locations

24 of 29 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 29 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartActual
Nov 4, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added. University of South Florida Health (USF) is now Terminated
Show 6 added (3 Canada, 2 United States, 1 South Korea)
  • Huntsville Hospital · Huntsville, United States
  • Clermont- Ambulatory Surgical Center · Clermont, United States
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) · Québec, Canada
  • Saint Michaels Hospital (Toronto) · Toronto, Canada
  • Vancouver General Hospital · Vancouver, Canada
  • Korea University Anam Hospital · Seoul, South Korea
across 2 updates, Oct 28, 2026 – Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of South Florida Health (USF) · Tampa, United StatesContact removed d•••@usf.edu · •••8001
Oct 28, 2026
Show all 2 updates
  1. Nov 12, 2026
    6 sites added
    Show 6 added (3 Canada, 2 United States, 1 South Korea)
    • Huntsville Hospital · Huntsville, United States
    • Clermont- Ambulatory Surgical Center · Clermont, United States
    • Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) · Québec, Canada
    • Saint Michaels Hospital (Toronto) · Toronto, Canada
    • Vancouver General Hospital · Vancouver, Canada
    • Korea University Anam Hospital · Seoul, South Korea
  2. Oct 28, 2026
    University of South Florida Health (USF) is now Terminated
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of South Florida Health (USF) · Tampa, United StatesContact removed d•••@usf.edu · •••8001

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06578104
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Nov 4, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Josman Suri
Contact
josman.suri@medtronic.com
7635050262
Khaldoun Tarakji, MD
study director · Medtronic CAS Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion